This study will be assessing the ability of PSMA-PET CT to determine the absence of
clinically significant prostate cancer in patients on active surveillance (AS) with low
risk and favorable intermediate-risk prostate cancer.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT05948657.
Locations matching your search criteria
United States
California
San Francisco
University of California San FranciscoStatus: Approved
Contact: UCSF Clinical Trials
Phone: 877-827-3222
This is a prospective, multicenter, nonrandomized single-arm study assessing the
diagnostic accuracy of PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission
Tomography-Computed Tomography) in determining the absence of clinically significant
prostate cancer in patients on active surveillance (AS).The trial will enroll 200
subjects for low and favorable intermediate-risk prostate cancer patients per NCCN
guidelines who have elected to pursue active surveillance.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationNYP/Weill Cornell Medical Center
Principal InvestigatorTimothy Mcclure
